Monoclonal gammopathy of undetermined significance diagnostic study of choice
|
Monoclonal gammopathy of undetermined significance Microchapters |
|
Differentiating Monoclonal gammopathy of undetermined significance from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Monoclonal gammopathy of undetermined significance diagnostic study of choice On the Web |
|
American Roentgen Ray Society Images of Monoclonal gammopathy of undetermined significance diagnostic study of choice |
|
FDA on Monoclonal gammopathy of undetermined significance diagnostic study of choice |
|
on Monoclonal gammopathy of undetermined significance diagnostic study of choice |
|
Monoclonal gammopathy of undetermined significance diagnostic study of choice in the news |
|
Blogs on Monoclonal gammopathy of undetermined significance diagnostic study of choice |
|
Directions to Hospitals Treating Monoclonal gammopathy of undetermined significance |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Omer Kamal, M.D.[2]
Overview
Study of choice
There is no single gold standard test for the diagnosis of monoclonal gammopathy of undetermined significance. Bone marrow aspiration and biopsy is donein all patients having M-protein level ≥1.5 g/dL.
Diagnostic Criteria
Non-IgM MGUS — Non-IgM MGUS (IgG, IgA, or IgD MGUS) is diagnosed by meeting the following three criteria
- Presence of a serum monoclonal protein (M-protein, whether IgA, IgG, or IgD), at a concentration <3 g/dL.
- Fewer than 10 percent clonal plasma cells in the bone marrow.
- The absence of lytic bone lesions, anemia, hypercalcemia, and renal insufficiency related to the plasma cell proliferative process.
IgM MGUS — IgM MGUS is diagnosed by meeting the following three criteria[1][2][3]
- Presence of a serum monoclonal protein (M-protein, whether IgA, IgG, or IgD), at a concentration <3 g/dL.[4]
- Fewer than 10 percent clonal lymphoplasmacytic/plasma cells in the bone marrow.
- The absence of end-organ damage such as anemia, constitutional symptoms, hyperviscosity, lymphadenopathy, or hepatosplenomegaly related to the plasma cell proliferative process
Light chain MGUS — Light chain MGUS (LC-MGUS) is diagnosed by meeting the following three criteria[2]
- The presence of an abnormal FLC ratio (ie, ratio of kappa to lambda FLCs <0.26 or >1.65)
- Increased level of the appropriate involved light chain (eg, increased kappa FLC in patients with a ratio >1.65 and increased lambda FLC in patients with a ratio <0.26)
- No monoclonal immunoglobulin heavy chain (IgG, IgA, IgD, or IgM)
- Fewer than 10 percent clonal lymphoplasmacytic cells in the bone marrow
- The absence of lytic bone lesions, anemia, hypercalcemia, and renal insufficiency related to the plasma cell proliferative process.
References
- ↑ "Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group". Br. J. Haematol. 121 (5): 749–57. June 2003. PMID 12780789.
- ↑ 2.0 2.1 Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E, Richardson P, Landgren O, Paiva B, Dispenzieri A, Weiss B, LeLeu X, Zweegman S, Lonial S, Rosinol L, Zamagni E, Jagannath S, Sezer O, Kristinsson SY, Caers J, Usmani SZ, Lahuerta JJ, Johnsen HE, Beksac M, Cavo M, Goldschmidt H, Terpos E, Kyle RA, Anderson KC, Durie BG, Miguel JF (November 2014). "International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma". Lancet Oncol. 15 (12): e538–48. doi:10.1016/S1470-2045(14)70442-5. PMID 25439696.
- ↑ Kyle RA (May 1978). "Monoclonal gammopathy of undetermined significance. Natural history in 241 cases". Am. J. Med. 64 (5): 814–26. PMID 645746.
- ↑ Kyle RA (November 1994). "The monoclonal gammopathies". Clin. Chem. 40 (11 Pt 2): 2154–61. PMID 7955402.